Company* (Country; Symbol) |
Funding Institution |
Amount (M) |
Type |
Details (Date) |
| ||||
Acambis plc (UK; ACAM) |
Centers for Disease Control and Prevention |
$30 |
Contract award |
Acambis will supply a further 10M doses of ACAM2000 smallpox vaccine, for $30M; Acambis previously supplied 182.5M doses (9/13) |
| ||||
Achaogen Inc.* |
U.S. Department of Defense |
$24.7 |
Defense Threat Reduction Agency contract |
DTRA funded the first year of a potential $24.7M four-year deal under which Achaogen will develop small-molecule therapies to treat anthrax and other biothreat agents (10/24) |
| ||||
Adnexus Therapeutics Inc.* |
National Institute of Arthritis and Musculoskeletal and Skin Diseases |
ND |
Phase I SBIR grant |
Funds will support development of Adnectin products, which are human fibronectin (9/5) |
| ||||
Alnylam Pharmaceuticals Inc. (ALNY) |
U.S. Department of Defense |
$1.1 |
Defense appropriation |
Funds will support development of RNAi therapeutics to combat natural or man-made biological threats (10/4) |
| ||||
Alnylam Pharmaceuticals Inc. (ALNY) |
National Institute of Allergy and Infectious Diseases |
$23 |
Contract |
The four-year award will support development of RNAi therapeutics as antiviral drugs targeting the Ebola virus (9/28) |
| ||||
Alnylam Pharmaceuticals Inc. (ALNY) |
National Institute of Allergy and Infectious Diseases |
$0.59 |
SBIR grant |
The one-year grant will support development of RNAi therapeutics as antivirals against multiple influenza strains, including the H5N1 virus (9/6) |
| ||||
Alteon Inc. (AMEX:ALT) |
Juvenile Diabetes Research Foundation |
ND |
Grant |
Funds will support Phase II trials being run by an Alteon collaborator in Australia, which will test the use of alagebrium on renal function in patients with Type I diabetes and microalbuminuria (7/10) |
| ||||
Althea Technologies Inc.* |
National Institute of Allergy and Infectious Diseases |
$0.91 |
Subcontract from Advanced BioScience Laboratories Inc. |
Althea got a manufacturing contract to produce a DNA-based HIV-1 vaccine (8/29) |
| ||||
Altor BioScience Corp.* |
National Cancer Institute |
$1.2 |
Phase II SBIR grant |
The two-year grant will support further development of processes for making therapeutic antibodies in transgenic lettuce (7/25) |
| ||||
Arbor Vita Corp.* |
National Institutes of Health |
$0.9 |
Phase II SBIR grant |
The two-year grant will fund work on an in vitro diagnostic test for cervical precancer and cancer, which is based on detection of the HPV-E6 oncoprotein (9/20) |
| ||||
Avanir Pharmaceuticals Inc. (AVNR) |
National Institute of Allergy and Infectious Diseases |
$2 |
Cooperative Research Partnerships for Biodefense grant |
Funding will support establishment of a cGMP manufacturing process and to test efficacy of the fully human monoclonal antibody AVP-21D9 against inhalation anthrax in non-human primates (6/30) |
| ||||
Avant Immunotherapeutics Inc. (AVAN) |
U.S. Department of Defense |
$2.6 |
Defense appropriation |
Funds will support continued development of an oral combination vaccine to protect against anthrax and plague (10/2) |
| ||||
Avant Immunotherapeutics Inc. (AVAN) |
National Institute of Allergy and Infectious Diseases |
$0.75 |
Phase II SBIR grant |
Funds will support further development and manufacture of Ty800, the company's single-dose, oral typhoid vaccine (9/27) |
| ||||
Avant Immunotherapeutics Inc. (AVAN) |
Bill and Melinda Gates Foundation |
$21 |
Funding support |
The International Vaccine Institute received the funding to conduct further clinical trials of Avant's CholeraGarde cholera vaccine in Bangladesh and India (8/2) |
| ||||
Axordia Ltd.* (UK) and Stem Cell Sciences Ltd. (UK; AIM:STEM) |
European Commission |
ND |
ESTOOLS program funding |
The companies are among those participating in the €12M ESTOOLS program focused on advancing the science surrounding human embryonic stem cells (8/28) |
| ||||
BioForce Nanosciences Holdings Inc. (OTC BB:BFNH) |
National Human Genome Research Institute |
$0.4 |
Funding award |
Funding will support development of the company's surface patterning tools; an additional $0.4M award is possible (9/26) |
| ||||
Bionovo Inc. (OTC BB:BNVI) |
National Institutes of Health |
$1 |
RO1 grant |
Funds will support research on a novel mechanism of nuclear transport regulation in cancer cells (7/12) |
| ||||
Biota Holdings Ltd. (Australia; ASX:BTA) |
National Institute of Allergy and Infectious Diseases |
$2.4 |
Contract award |
Biota got $2.4M of a potential $8.5M over four years for development of a long-acting class of neuraminidase inhibitors, named FluNet (8/8) |
| ||||
Biothera* |
National Institutes of Health |
$3.6 |
SBIR Advanced Technology Grant |
Biothera got funding for Phase I of a five-year $3.6M program to develop its Imprime WGP drug to treat bone marrow injury from acute radiation exposure (9/5) |
| ||||
Brain AG* (Germany) |
German government |
ND |
BioChance Plus research grant |
The company and university groups will develop high-throughput systems in the area of industrially relevant biocatalysts (7/26) |
| ||||
Cangene Corp. (Canada; TSX:CNJ) |
U.S. Department of Health and Human Services |
$143 |
Project BioShield contract |
Cangene will provide 10,000 doses of anthrax immune globulin over three years under a modification to a September 2005 contract (7/28) |
| ||||
Celera Genomics (NYSE:CRA) |
National Institutes of Health |
$0.9 |
Grant |
Funds will support development of an in vitro diagnostic test for the H5N1 influenza virus (8/21) |
| ||||
Cepheid Inc. (CPHD) |
National Institute of Allergy and Infectious Diseases |
ND |
Phase II STTR grant |
Cepheid and the University of Medicine and Dentistry of New Jersey will use the funds in development of a PCR-based test for tuberculosis (8/30) |
| ||||
ChemDiv Inc.* and Yale University |
National Institutes of Health |
ND |
Phase II grant |
ChemDiv and Yale University were awarded the funding to further develop small-molecule inhibitors of the melanocortin-2 receptor GPCR (8/30) |
| ||||
Cleveland BioLabs Inc. (CBLI) |
National Cancer Institute |
$0.75 |
Phase II SBIR contract |
Funds will support development of small-molecule radioprotectors, to reduce cell damage from radiation exposure (9/6) |
| ||||
CombiMatrix Group (CBMX) |
U.S. Department of Defense |
$2 |
Defense appropriations |
Two allocations of $1M each will support continued development of microarray technologies for detecting biological-threat agents and infectious pathogens, such as the H5N1 influenza virus (10/9) |
| ||||
Crucell NV (the Netherlands; CRXL) |
National Institute of Allergy and Infectious Diseases |
$16.2 |
Contract award |
Funding supports work with Beth Israel Deaconess Medical Center and Charles River Laboratories Inc. on development of an HIV vaccine that uses live vectors (10/9) |
| ||||
Cyto Pulse Sciences Inc.* |
National Institute of Allergy and Infectious Diseases |
$2 |
Phase II grant |
The two-year award will fund development of the company's Easy Vax DNA vaccine delivery system, for use against biodefense pathogens (8/16) |
| ||||
CytRx Corp. (CYTR) |
National Institute of Diabetes and Digestive and Kidney Diseases |
$0.22 |
SBIR grant |
Funds will support development of inhibitors to fatty acid synthase for the treatment of Type II diabetes and obesity (9/27) |
| ||||
Develogen AG* (Germany) |
Ministry of Industry, Trade and Labor (Israel) |
€0.475 ($0.6) |
Grant |
The grant continues support being provided to DeveloGen's subsidiary in Israel for the DiaPep277 program for treating autoimmune diabetes (7/4) |
| ||||
DOR BioPharma Inc. (OTC BB:DORB) |
National Institute of Allergy and Infectious Diseases |
$4.8 |
Grant |
Funds will support continued development of RiVax, a recombinant vaccine against ricin toxin (9/29) |
| ||||
DOR BioPharma Inc. (OTC BB:DORB) |
National Institute of Allergy and Infectious Diseases |
$0.5 |
Phase I SBIR grant |
Funds will support research on BT-VACC, a multivalent mucosal vaccine against botulinum toxin (9/29) |
| ||||
Emergent BioSolutions Inc.* |
National Institute of Allergy and Infectious Diseases |
$3.8 |
Grants |
Two grants totaling $3.8M will support development of the company's anthrax immune globulin therapeutic (8/31) |
| ||||
Epeius Biotechnologies Corp.* |
U.S. FDA |
ND |
Grant |
Funds will support research on pharmacology and toxicology of the gene therapy agent Rexin-G in patients with advanced pancreatic cancer (10/2) |
| ||||
Evogenix Ltd. (Australia; ASX:EGX) |
Australian government |
A$1.66 ($1.2) |
Commercial Ready grant |
The two-year grant will support development of DMF10, an anticancer hamster antibody (7/5) |
| ||||
FibroGen Inc.* |
National Heart, Lung and Blood Institute |
ND |
Phase II SBIR grant |
Funds will support development of hypoxia-inducible factor prolyl hydroxylase inhibitors for treating sickle cell disease (8/22) |
| ||||
Galapagos NV (Belgium; Euronext:GLPG) |
Flanders government (Belgium) |
€1.8 ($2.3) |
Grant |
Funds will support development of biological models for treating rheumatoid arthritis and osteoporosis; Galapagos will work with three Belgian institutions on the programs (7/26) |
| ||||
GeneGo Inc.* |
National Cancer Institute |
ND |
Phase II SBIR grant |
Funds will support work with the Mayo Clinic on discovery of biomarkers implicated in breast cancer (10/3) |
| ||||
GeneGo Inc.* |
U.S. Department of Defense |
$0.75 |
Phase II SBIR grant |
Funds will support development of a systems biology suite for functional analysis of proteomics data (8/8) |
| ||||
Genomatix Software GmbH* (Germany) |
Federal Ministry of Education and Research (Germany) |
$1.6 |
BioChance research contract |
The company and two academic partners got two years of fundings for research in RNAi-mediated regulatory networks (9/14) |
| ||||
GenVec Inc. (GNVC) |
National Institute of Allergy and Infectious Diseases |
$3.56 |
Subcontract award from SAIC-Frederick Inc. |
Additional funds under the deal with the NIAID's Vaccine Research Center will support development of adenovector-based HIV vaccines (10/10) |
| ||||
GenVec Inc. (GNVC) |
National Institute of Allergy and Infectious Diseases |
$0.43 |
Phase I SBIR grant |
The Biodefense Program funds will support development of an adenovector-based vaccine technology (8/29) |
| ||||
GTC Biotherapeutics Inc. (GTCB) |
National Institutes of Health |
$1.4 |
SBIR grant |
GTC got additional funds for its CD137 monoclonal antibody program, which targets solid tumors and autoimmune diseases (10/5) |
| ||||
Helicos BioSciences Corp.* |
National Human Genome Research Institute |
$2 |
Grant |
Funds will support fund research of a single-molecule sequencing technology for low-cost resequencing applications and de novo sequencing of large genomes (10/4) |
| ||||
Immatics Biotechnologies GmbH* (Germany) |
Federal Ministry of Education and Research (Germany) |
€0.57 ($0.71) |
Grants |
Grants will support preclinical development of a therapeutic vaccine for pancreatic cancer, and development of a process for isolating tumor-specific T cells from cancer patients (9/6) |
| ||||
Immunotope Inc.* |
U.S. Army |
$0.78 |
Phase II SBIR grant |
Funds will be used in development of an autoantibody-based, early stage diagnostic test for prostate cancer (10/23) |
| ||||
Inovio Biomedical Corp. (AMEX:INO) |
U.S. Department of Defense |
$1.1 |
Defense appropriation |
For development of its electroporation-based gene delivery technology for vaccination against infectious diseases, including bioterrorism agents (10/19) |
| ||||
Invitrogen Corp. (IVGN) |
U.S. Department of Defense |
$1.24 |
Contract award |
Funding is an extension to existing contract to support research on protein microarray technology to detect and analyze biothreat agents (9/12) |
| ||||
Javelin Pharmaceuticals Inc. (AMEX:JAV) |
National Cancer Institute |
$0.75 |
Phase II SBIR grant |
Funds will support clinical development of PMI-150 (intranasal ketamine) for treating pain (7/7) |
| ||||
Juvaris BioTherapeutics Inc.* |
National Cancer Institute |
ND |
Phase I SBIR grant |
One-year grant will support work with Penn State College of Medicine on a therapeutic vaccine approach for treating acute myelogenous leukemia (9/26) |
| ||||
Juvaris BioTherapeutics Inc.* |
National Institute of Allergy and Infectious Diseases |
$1 |
Phase I SBIR grant |
One-year grant will support work with Colorado State University to develop approach for treating F. tularensis (tularemia), a priority pathogen (9/13) |
| ||||
Lentigen Corp.* |
National Institutes of Health |
ND |
Phase I SBIR grant |
For evaluation of using lentiviral-engineered T cells that express chimeric receptors and signaling modules to improve efficacy of cancer therapies directed against the tumor-associated antigen mesothelin (10/17) |
| ||||
Lexicon Genetics Inc. (LEXG) |
U.S. Defense Advanced Research Projects Agency |
ND |
Funding award |
Lexicon will work to identify targets for drug discovery efforts in the area of sleep deprivation, under a one-year contract (9/26) |
| ||||
LigoCyte Pharmaceuticals Inc.* |
U.S. Department of Defense |
$2.3 |
Contract award |
Funding will support continued validation of a third-generation mucosal anthrax vaccine (7/6) |
| ||||
MacroGenics Inc.* |
National Institute of Allergy and Infectious Diseases |
$50 |
Contract award |
The five-year award will support development of a preclinical monoclonal antibody to West Nile virus through Phase II trials (10/3) |
| ||||
MacroGenics Inc.* |
National Institute of Allergy and Infectious Diseases |
$6.8 |
Grant |
Funds of up to $6.8M will be used to support development of a monoclonal antibody against smallpox virus, in collaboration with the NIAID (10/3) |
| ||||
MacroGenics Inc.* |
National Institute of Allergy and Infectious Diseases |
$6 |
Subcontract from St. Jude Children's Research Hospital |
Up to $6M will be awarded for development of cross-neutralizing monoclonal antibodies specific for the H5N1 influenza virus (10/3) |
| ||||
MaxThera Inc.* |
National Institute of Allergy and Infectious Diseases |
$0.76 |
Phase I SBIR grant |
The two-year grant will support efforts to design and develop antibiotics against potential lethal infections complicated by antibiotic resistance (9/22) |
| ||||
Nastech Pharmaceutical Co. Inc. (NSTK) |
National Institute of Allergy and Infectious Diseases |
ND |
Phase I SBIR grant |
Funds will be used for further development of small-interfering RNA therapeutics to prevent and treat influenza (9/29) |
| ||||
Omicia Inc.* |
National Human Genome Research Institute |
$0.79 |
Phase II SBIR grant |
Funds will be used to refine the disease marker genome annotation system prototyped by the company during Phase I of the grant (9/13) |
| ||||
PharmAthene Inc.* |
National Institutes of Health |
$1.7 |
Countermeasures Against Chemical Threats grant |
Funds will support continued development of the broad-spectrum chemical nerve agent therapy, Protexia, a recombinant form of human butyrylcholinesterase (10/18) |
| ||||
PharmAthene Inc.* and Medarex Inc. (MEDX) |
U.S. Department of Defense |
$1 |
Defense appropriation |
Funds will support ongoing development of Valortim, a fully human monoclonal antibody being developed for anthrax infection (10/11) |
| ||||
PharmAthene Inc.* |
Department of Defense, U.S Army Space and Missile Command |
$34.7 |
Contract |
Multiyear contract worth up to $213M is for development of the broad-spectrum chemical nerve agent prophylaxis, Protexia; $34.7M already was allocated (9/25) |
| ||||
Pluristem Life Systems Inc. (Israel; OTC BB:PLRS) |
Ministry of Trade and Industry (Israel) |
$0.47 |
Grant |
The royalty-bearing grant will support development of Pluristem's stem cell product PLX-I, which may have use in bone marrow transplants (8/24) |
| ||||
Pressure BioSciences Inc. (PBIO) |
National Institutes of Health |
$0.149 |
Phase I SBIR grant |
Grant will help fund experiments on a pressure cycling technology for use in extracting protein biomarkers, subcellular molecular complexes and organelles from cells and tissues (10/4) |
| ||||
ProlX Pharmaceuticals Corp.* |
National Institutes of Health |
$4.5 |
Phase II SBIR grants |
Two grants totaling about $4.5M were awarded for clinical and preclinical development of the cancer drugs PX-12 and PX-866, respectively (7/31) |
| ||||
ProNAi Therapeutics Inc.* |
Michigan Economic Development Corp. |
$3.3 |
21st Century Jobs Fund award |
Funding will support development of nucleic-acid drugs based on DNA interference (9/12) |
| ||||
Protiva Biotherapeutics Inc.* (Canada) |
U.S. Defense Threat Reduction Agency |
$1.4 |
Grant |
Protiva is part of a consortium that together is getting $3.6M to develop a therapy for hemorrhagic fever viral infection; it includes the U.S. Army Medical Research Institute of Infectious Diseases (9/19) |
| ||||
PTC Therapeutics Inc.* |
Office of Orphan Products Development of the FDA |
ND |
Grant |
Funds will support patient-related costs of ongoing Phase II trial of PTC124 for treating nonsense-mutation-mediated Duchenne muscular dystrophy (10/19) |
| ||||
PTC Therapeutics Inc.* |
U.S. Defense Threat Reduction Agency |
$17.2 |
Funding award |
Funds will go toward discovery and development of broad-spectrum small-molecule antibacterials against biowarfare or bioterrorism agents (10/2) |
| ||||
PTC Therapeutics Inc.* |
U.S. Department of Defense |
$2.2 |
Grant |
The three-year grant will be used on development of PTC299 as a treatment for breast cancer (9/26) |
| ||||
QBI Life Sciences (division of Quintessence Biosciences Inc.) |
National Institutes of Health |
ND |
Phase I grant |
QBI will work with GWC Technologies to develop an assay that provides absorption profiles for early stage drug candidates (7/14) |
| ||||
Regeneron Pharmaceuticals Inc. (REGN) |
National Institutes of Health |
ND |
Grant |
Regeneron will use its VelociGene technology to target 3,500 genes under a five-year grant related to the NIH's Knockout Mouse Project (9/7) |
| ||||
RegeneRx Bio-pharmaceuticals Inc. (AMEX:RGN) |
FDA's Office of Orphan Products Development |
$0.545 |
Grant |
Fund will support clinical development of its drug candidate based on thymosin beta 4 for treating the rare genetic disease epidermolysis bullosa (8/9) |
| ||||
Rx3 Pharmaceuticals Inc.* |
National Institutes of Health |
$1.5 |
Grants |
Two grants totaling $1.5M will help fund work in the area of antibiotic development (9/25) |
| ||||
SIGA Technologies Inc. (SIGA) |
National Institute of Allergy and Infectious Diseases |
$16.5 |
Contract award |
Three-year funding will support development of its smallpox drug candidate SIGA-246 (10/4) |
| ||||
SIGA Technologies Inc. (SIGA) |
National Institutes of Health |
$6 |
Grant |
Funding will support development of antiviral drugs for Lassa fever virus (9/12) |
| ||||
SIGA Technologies Inc.(SIGA) |
National Institutes of Health |
$4.8 |
Phase II SBIR grant |
Funding will support clinical development of its smallpox drug candidate SIGA-246 (8/2) |
| ||||
Syntaxin Ltd.* (UK) |
UK Department for Trade and Industry |
£1.2 ($2.2) |
Collaborative R&D grant |
Syntaxin, University College London and the UK Health Protection Agency will work to develop enhanced methods for bioprocessing complex proteins, for use as drugs (7/6) |
| ||||
Tissue Genesis Inc.* |
U.S. Department of Defense |
$4.5 |
Contract award |
Funding will support continued research and development on cell recovery and cell delivery systems (9/18) |
| ||||
VASTox plc (UK; AIM:VOX) |
UK Department of Trade and Industry |
£0.37 ($0.69) |
Matching grant |
Funding, including academic collaboratories, totaled £0.91M, for a research program in stem cells (9/20) |
| ||||
Velcura Therapeutics Inc.* |
National Institute on Aging |
$0.274 |
Phase I SBIR grant |
Funds will be used to further identify the genes and/or protein networks modulated during human bone formation (8/30) |
| ||||
Xechem International Inc. (OTC BB:XKEM) |
National Heart, Lung and Blood Institute |
$0.473 |
SBIR grant |
Funds will support toxicity studies on 5-HMF, a five-membered heterocyclic anti-sickling compound (10/4) |
| ||||
XOMA Ltd. (XOMA) |
National Institute of Allergy and Infectious Diseases |
$16 award |
Contract |
Funding will support pre-Phase I development of monoclonal antibodies for treating botulism resulting from bioterrorism (7/31) |
| ||||
Notes: | ||||
* Indicates a privately held company. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. |